XRAY
DENTSPLY SIRONA Inc. Healthcare - Dental Products Investor Relations →
DENTSPLY SIRONA Inc. (XRAY) closed at $10.33 as of 2026-06-19, trading 55.5% below its 200-week moving average of $23.21. This places XRAY in the extreme value zone. The stock moved further from the line this week, up from -56.7% last week. The 14-week RSI sits at 40, indicating neutral momentum.
Trading volume is running at 1.0x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.87 ratio) is neutral — neither side is clearly dominating.
Over the past 1979 weeks of data, XRAY has crossed below its 200-week moving average 23 times. On average, these episodes lasted 22 weeks. Historically, investors who bought XRAY at the start of these episodes saw an average one-year return of +18.2%.
With a market cap of $2.1 billion, XRAY is a mid-cap stock. The company generates a free cash flow yield of 6.3%, which is healthy. Return on equity stands at -37.7%. The stock trades at 1.5x book value.
The company has been aggressively buying back shares, reducing its share count by 7.3% over the past three years.
Over the past 33.5 years, a hypothetical investment of $100 in XRAY would have grown to $168, compared to $3097 for the S&P 500. XRAY has returned 1.6% annualized vs 10.8% for the index, underperforming the broader market over this period.
In the past 12 months, corporate insiders have made 10 open-market purchases totaling $1,639,597. Multiple insiders purchased within a 30-day window — a cluster buy pattern that historically signals management confidence in the company's prospects. Notably, these purchases occurred while XRAY is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.
Free cash flow has been declining at a -34.4% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: XRAY vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After XRAY Crosses Below the Line?
Across 20 historical episodes, buying XRAY when it crossed below its 200-week moving average produced an average return of +6.5% after 12 months (median +9.0%), compared to +16.5% for the S&P 500 over the same periods. 60% of those episodes were profitable after one year. After 24 months, the average return was +25.1% vs +27.9% for the index.
Each line shows $100 invested at the moment XRAY crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices XRAY would reach each dislocation threshold.
Dislocation Price Levels
Prices where XRAY's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-05-05.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $9.86 | Unusually cheap — potential buy zone |
| Value | +1σ | $10.84 | Cheap vs. own history |
| Fair Value | +0σ | $12.03 | Historical mean behavior |
| Expensive | -1σ | $13.52 | Expensive vs. own history |
| Deep Expensive | -2σ | $15.44 | Unusually expensive — potential trim zone |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from XRAY's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
XRAY has crossed below its 200-week MA 23 times with an average 1-year return of +18.2% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Aug 1988 | Aug 1988 | 1 | 1.5% | +31.2% | +1946.0% |
| Oct 1988 | Jul 1989 | 37 | 16.7% | +38.7% | +2012.0% |
| Oct 1990 | Nov 1990 | 1 | 2.2% | +197.3% | +1669.5% |
| Dec 1994 | Dec 1994 | 1 | 0.7% | +30.1% | +187.1% |
| Sep 1998 | Oct 1998 | 6 | 8.2% | +14.2% | +82.6% |
| Mar 1999 | Apr 1999 | 3 | 4.2% | +23.6% | +70.6% |
| Aug 1999 | Aug 1999 | 1 | 0.1% | +41.9% | +61.1% |
| Sep 1999 | Jan 2000 | 20 | 13.6% | +51.5% | +70.7% |
| Oct 2008 | Aug 2009 | 45 | 31.6% | +18.6% | -58.7% |
| Oct 2009 | Nov 2009 | 1 | 1.1% | -4.2% | -62.4% |
| Nov 2009 | Nov 2009 | 2 | 1.6% | -5.0% | -62.3% |
| Jan 2010 | Mar 2010 | 5 | 3.4% | +7.3% | -63.1% |
| May 2010 | Dec 2010 | 32 | 15.0% | +14.0% | -63.5% |
| Aug 2011 | Aug 2011 | 2 | 6.7% | +14.8% | -63.8% |
| Sep 2011 | Oct 2011 | 6 | 8.9% | +15.7% | -62.3% |
| Nov 2011 | Nov 2011 | 1 | 1.5% | +20.5% | -62.7% |
| Aug 2017 | Aug 2017 | 1 | 2.9% | -26.3% | -77.6% |
| Mar 2018 | Apr 2019 | 59 | 38.3% | -12.1% | -79.0% |
| May 2019 | Jun 2019 | 3 | 1.3% | -30.2% | -78.5% |
| Jul 2019 | Oct 2019 | 13 | 6.9% | -14.8% | -77.9% |
| Feb 2020 | Nov 2020 | 39 | 38.8% | +8.8% | -76.4% |
| Nov 2021 | Nov 2021 | 1 | 0.6% | -36.0% | -77.0% |
| Mar 2022 | Ongoing | 224+ | 63.3% | Ongoing | -76.5% |
| Average | 22 | — | +18.2% | — |
Frequently Asked Questions
Is XRAY below its 200-week moving average?
Yes. As of 2026-06-19, DENTSPLY SIRONA Inc. (XRAY) is trading 55.5% below its 200-week moving average of $23.21. The current price is $10.33.
What is XRAY's 200-week moving average price?
DENTSPLY SIRONA Inc.'s 200-week moving average is $23.21 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when XRAY drops below its 200-week moving average?
XRAY has crossed below its 200-week moving average 23 times in our data. On average, buying at that moment produced a one-year return of +18.2%. These dips have historically been decent entry points. These episodes lasted 22 weeks on average.
Is XRAY a good value right now?
Here's what our data says about XRAY as of 2026-06-19: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 40. Free cash flow yield is 6.3%. Return on equity is -37.7%. Price-to-book is 1.5x. This is not a buy or sell recommendation — always do your own research.
How does XRAY compare to the S&P 500?
Over the past 33.5 years, $100 invested in XRAY would have grown to $168, compared to $3097 for the S&P 500. That's 1.6% annualized vs 10.8% for the index. XRAY has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19